FINWIRES · TerminalLIVE
FINWIRES

Cantor Fitzgerald Upgrades Capricor Therapeutics to Overweight From Neutral, Adjusts PT to $28 From $3.50

By

Capricor Therapeutics (CAPR) has an average rating of hold and mean price target of $26.12, according to analysts polled by FactSet.

(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)

Related Articles